Advantages and Disadvantages of Isoprenaline

  • M. Thomas
Part of the Boerhaave Series for Postgraduate Medical Education book series (BSPM, volume 7)


For more than ten years isoprenaline has been used in practical clinical therapeutics in a variety of circumstances. Its application depends upon two major pharmacological characteristics. First its chronotropic effect and its ability to arouse, accelerate and maintain natural and abnormal pacemaker activity (1) and second its inotropic property (2). Dose for dose, isoprenaline probably ranks as the most powerful inotropic agent available for clinical use. It is a pure beta-activator and as such is associated with peripheral vasodilatation as well as its dominant cardio-stimulatory properties. This becomes particularly relevant in its use in the various states of cardiovascular failure.


Acute Myocardial Infarction Acute Heart Failure Sinus Bradycardia Mitral Valve Disease Cardiovascular Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vogel, J. H. K., Use of isoproterenol in the treatment of complete heart block complicating acute myocardial infarction. Amer. J. Cardiol. 7, 746 (1961).PubMedCrossRefGoogle Scholar
  2. 2.
    Lands, A. M. & Howard, J. W., A comparative study of the effect of L-arterenol, epinephrine and isopropylartenerol on the heart. J. Pharmacol, exp. Ther. 106, 65 (1952).Google Scholar
  3. 3.
    James, T. N., Posterior myocardial infarction. J. Michigan State Med. Soc. 60, 1409 (1961).Google Scholar
  4. 4.
    Thomas, M. & Woodgate, D., Effect of atropine on bradycardia and hypotension in acute myocardial infarction. Brit. Heart J. 3, 28, 409 (1966).CrossRefGoogle Scholar
  5. 5.
    Adgey, A. A., Geddes, J. S., Mulholland, H. C., Kecgan, D. A. J. & Pantridge, J. F., Incidence, significance and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet 2, 1097 (1968).PubMedCrossRefGoogle Scholar
  6. 6.
    Lown, B., Fakhro, A. M., Hood, W. B. & Thorn, G. W., The coronary care unit. J. Amer. med. Ass. 3, 119, 156 (1967).Google Scholar
  7. 7.
    Zoll, P. M., Linanthal, A. J., Gibson, W., Paul, M. H. & Norman, L. R., Intravenous drug therapy of Stokes-Adams disease. Effects of sympathomimeticamines on ventricular rhythmicity and atrio-ventricular conduction. Circulation 27, 325 (1963).Google Scholar
  8. 8.
    Hatle, L. & Rokseth, R., Conservative treatment of A-V block in acute myocardial infarction. Results in 105 consecutive patients. Brit. Heart J. 33, 595 (1971).PubMedCrossRefGoogle Scholar
  9. 9.
    Furman, S., Fundamentals of cardiac pacing. Amer. Heart J. 73, 2, 261 (1967).PubMedCrossRefGoogle Scholar
  10. 10.
    Linanthal, A. J. & Zoll, P. M., Prevention of ventricular tachycardia and fibrillation by intravenous isoproterenol and epinephrine. Circulation 27, 5 (1963).Google Scholar
  11. 11.
    Han, J., De Traglia, J., Millet, D. & Moe, G. J., Incidence of atopic beats as a function of the basic rate in the ventricle. Amer. Heart J. 72, 632 (1966).PubMedCrossRefGoogle Scholar
  12. 12.
    Gleason, W. J. & Braunwald, E., Studies on the first derivative of the ventricular pulse in man. J. clin. Invest. 41, 80 (1962).PubMedCrossRefGoogle Scholar
  13. 13.
    Reeves, T. J., Hefner, L. L., Jones, W. B., Coghlan, C., Prieto, G. & Carroll, J., The haemodynamic determinants of the rate of change of pressure in the left ventricle during isometric contraction. Amer. Heart J. 60, 745 (1960).PubMedCrossRefGoogle Scholar
  14. 14.
    Dodge, H. P., Lord, J. D. & Sandler, H., Cardiovascular effects of isoproterenol in normal subjects and patients with congestive heart failure. Amer. Heart J. 60, 94 (1960).PubMedCrossRefGoogle Scholar
  15. 15.
    Elliott, W. C. & Gorlin, R., Isoproterenol in the treatment of heart disease. J. Amer. med. Ass. 197, 315 (1966).CrossRefGoogle Scholar
  16. 16.
    Sampson, J. J. & Hutchinson, J. C., Heart failure in myocardial infarction. Progr. cardiovasc. Dis. 10, 11 (1967).CrossRefGoogle Scholar
  17. 17.
    Kaiser, G. A., Ross, J. Jr. & Braunwald, E., Alpha and beta adrenergic receptor mechanisms in the systemic venous bed. J. Pharmacol, exp. Ther. 144, 156 (1964).Google Scholar
  18. 18.
    Braunwald, E., Thirteenth Bowditch Lecture. The determinants of myocardial oxygen consumption. Physiologist 12, 65 (1969).PubMedGoogle Scholar
  19. 19.
    Niles, N. R., Zavin, J. D. & Norikado, R. N., Histochemical study of effects of hypoxia and isoproterenol on rat myocardium. Amer. J. Cardiol. 22, 381 (1968).PubMedCrossRefGoogle Scholar
  20. 20.
    Maroko, P. R., Kjekshus, J. K., Sobel, B. E., Watanabe, T., Covell, J. W., Ross, J. & Braunwald, E., Factors influencing infarct size following experimental coronary artery occlusion. Circulation 43, 67 (1971).PubMedGoogle Scholar

Copyright information

© Leiden University Press, Leiden, The Netherlands 1972

Authors and Affiliations

  • M. Thomas

There are no affiliations available

Personalised recommendations